University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, Cologne, Germany.
Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
Clin Pharmacol Ther. 2019 Dec;106(6):1398-1407. doi: 10.1002/cpt.1564. Epub 2019 Aug 12.
A new probe drug cocktail containing substrates of important drug transporters was tested for mutual interactions in a clinical trial. The cocktail consisted of (predominant transporter; primary phenotyping metric): 10 mg adefovir-dipivoxil (OAT1; renal clearance (CL )), 100 mg sitagliptin (OAT3; CL ), 500 mg metformin (several renal transporters; CL ), 2 mg pitavastatin (OATP1B1; clearance/F), and 0.5 mg digoxin (intestinal P-gp, renal P-gp, and OATP4C1; peak plasma concentration (C ) and CL ). Using a randomized six-period, open change-over design, single oral doses were administrated either concomitantly or separately to 24 healthy male and female volunteers. Phenotyping metrics were evaluated by noncompartmental analysis and compared between periods by the standard average bioequivalence approach (boundaries for ratios 0.80-1.25). Primary metrics supported the absence of relevant interactions, whereas secondary metrics suggested that mainly adefovir was a victim of minor drug-drug interactions (DDIs). All drugs were well tolerated. This cocktail may be another useful tool to assess transporter-based DDIs in vivo.
一种新的探针药物鸡尾酒,包含重要药物转运体的底物,在临床试验中被测试其相互作用。该鸡尾酒由以下成分组成(主要转运体;主要表型指标):10 毫克阿德福韦酯(OAT1;肾清除率(CL))、100 毫克西他列汀(OAT3;CL)、500 毫克二甲双胍(多种肾转运体;CL)、2 毫克匹伐他汀(OATP1B1;清除率/F)和 0.5 毫克地高辛(肠 P-糖蛋白、肾 P-糖蛋白和 OATP4C1;峰血浆浓度(C)和 CL)。采用随机六周期、开放交叉设计,24 名健康男性和女性志愿者分别或同时口服单剂量给药。表型指标通过非房室分析进行评估,并通过标准平均生物等效性方法(比值 0.80-1.25 的界限)在各周期之间进行比较。主要指标支持不存在相关的相互作用,而次要指标表明主要是阿德福韦是轻微药物-药物相互作用(DDI)的受害者。所有药物均耐受良好。这种鸡尾酒可能是另一种用于评估体内基于转运体的 DDI 的有用工具。